Literature DB >> 18508826

Can CAP guideline adherence improve patient outcome in internal medicine departments?

F Blasi1, I Iori, A Bulfoni, S Corrao, S Costantino, D Legnani.   

Abstract

The impact of compliance with Italian guidelines on the outcome of hospitalised community-acquired pneumonia (CAP) in internal medicine departments was evaluated. All Fine class IV or V CAP patients were included in this multicentre, interventional, before-and-after study, composed of three phases: 1) a retrospective phase (RP; 1,443 patients); 2) a guideline implementation phase; and 3) a prospective phase (PP; 1,404 patients). Antibiotic prescription according to the guidelines increased significantly in the PP. The risk of failure at the end of the firstline therapy was significantly lower in the PP versus the RP (odds ratio (OR) 0.83, 95% confidence interval (CI) 0.69-1.00), particularly in Fine class V patients (OR 0.71, 95% CI 0.51-0.98). Analysis of outcome in the overall population (2,847 patients) showed a statistically significant advantage for compliant versus noncompliant therapies in terms of failure rate (OR 0.74, 95% CI 0.60-0.90) and an advantage in terms of mortality (OR 0.77, 95% CI 0.58-1.04). Antipneumococcal cephalosporin monotherapy was associated with a low success rate (68.6%) and the highest mortality (16.2%); levofloxacin alone and the combination of cephalosporin and macrolide resulted in higher success rates (79.1 and 76.7%, respectively) and significantly lower mortalities (9.1 and 5.7%, respectively). Overall, a low compliance with guidelines in the prospective phase (44%) was obtained, indicating the need for future more aggressive and proactive approaches.

Entities:  

Mesh:

Year:  2008        PMID: 18508826     DOI: 10.1183/09031936.00092607

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  11 in total

1.  A tailored implementation strategy to reduce the duration of intravenous antibiotic treatment in community-acquired pneumonia: a controlled before-and-after study.

Authors:  M F Engel; A H W Bruns; M E J L Hulscher; C A J M Gaillard; S U C Sankatsing; F Teding van Berkhout; M H Emmelot-Vonk; E M Kuck; M H M Steeghs; J H den Breeijen; R K Stellato; A I M Hoepelman; J J Oosterheert
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-05-26       Impact factor: 3.267

2.  Severe community-acquired pneumonia and positive urinary antigen test for S. pneumoniae: amoxicillin is associated with a favourable outcome.

Authors:  V Blanc; A Mothes; A Smetz; I Timontin; M D Guardia; A Billiemaz; J Dellamonica; M Vassallo; D Néri; S Chadapaud; A-L Toyer; P Del Guidice; A Fribourg; S Léotard; I Nicolle; P-M Roger
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-10-17       Impact factor: 3.267

3.  Adherence to guidelines for hospitalized community-acquired pneumonia over time and its impact on health outcomes and mortality.

Authors:  Elisa Costantini; Elias Allara; Filippo Patrucco; Fabrizio Faggiano; Fozia Hamid; Piero Emilio Balbo
Journal:  Intern Emerg Med       Date:  2016-04-20       Impact factor: 3.397

4.  [Pneumonia in the elderly: results of quality improvement program for a geriatric department in Lower Saxony 2006-2009].

Authors:  M Gogol; D Schmidt; A Dettmer-Flügge; B Vaske
Journal:  Z Gerontol Geriatr       Date:  2011-08       Impact factor: 1.281

5.  Community-acquired pneumonia: impact of empirical antibiotic therapy without respiratory fluoroquinolones nor third-generation cephalosporins.

Authors:  J Pradelli; K Risso; F G de Salvador; E Cua; R Ruimy; P-M Roger
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-10-02       Impact factor: 3.267

6.  A prospective study of inpatients to determine microbial etiology and therapeutic outcome of antibiotics for community-acquired pneumonia in pakistan.

Authors:  Sahar Rehman; Kanwal Rehman; Muhammad Sajid Hamid Akash
Journal:  Bioimpacts       Date:  2013-06-23

7.  Compliance with guidelines-recommended processes in pneumonia: impact of health status and initial signs.

Authors:  Rosario Menéndez; Antoni Torres; Soledad Reyes; Rafael Zalacain; Alberto Capelastegui; Olga Rajas; Luis Borderías; Juan J Martín-Villasclaras; Salvador Bello; Inmaculada Alfageme; Felipe Rodríguez de Castro; Jordi Rello; Luis Molinos; Juan Ruiz-Manzano
Journal:  PLoS One       Date:  2012-05-22       Impact factor: 3.240

8.  Azithromycin combination therapy for community-acquired pneumonia: propensity score analysis.

Authors:  Akihiro Ito; Tadashi Ishida; Hiromasa Tachibana; Hironobu Tokumasu; Akio Yamazaki; Yasuyoshi Washio
Journal:  Sci Rep       Date:  2019-12-05       Impact factor: 4.379

9.  Current management of patients hospitalized with community-acquired pneumonia across Europe: outcomes from REACH.

Authors:  Francesco Blasi; Javier Garau; Jesús Medina; Marco Ávila; Kyle McBride; Helmut Ostermann
Journal:  Respir Res       Date:  2013-04-15

10.  Clinical Pathway and Monthly Feedback Improve Adherence to Antibiotic Guideline Recommendations for Community-Acquired Pneumonia.

Authors:  Maher Almatar; Gregory M Peterson; Angus Thompson; Duncan McKenzie; Tara Anderson; Syed Tabish R Zaidi
Journal:  PLoS One       Date:  2016-07-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.